Hemochromatosis genes and other factors contributing to the pathogenesis of porphyria cutanea tarda
Open Access
- 1 March 2000
- journal article
- Published by American Society of Hematology in Blood
- Vol. 95 (5), 1565-1571
- https://doi.org/10.1182/blood.v95.5.1565.005k42_1565_1571
Abstract
Inherited and acquired factors have been implicated in the pathogenesis of porphyria cutanea tarda (PCT), a disorder characterized by a photosensitive dermatosis and hepatic siderosis. This study, comprising 108 patients with PCT, was intended to define the role of hemochromatosis gene (HFE) mutations in the expression of PCT and to determine the contribution of acquired factors including alcohol, hepatitis C virus (HCV), and estrogen. The 2 known HFEmutations, cysteine 282 tyrosine (Cys282Tyr) and histidine 63 asparagine (His63Asp), were detected by polymerase chain reaction, and anti-HCV immunoglobulin G was detected serologically. Liver biopsies were graded for iron content, inflammation, and fibrosis. Estimates of alcohol and estrogen use were based on a questionnaire. Of the PCT patients tested, 19% were homozygous for the Cys282Tyr mutation; controls were equal to 0.5%. The compound heterozygous genotype was detected in 7% of the PCT patients; controls were less than 1%. The transferrin saturation, serum ferritin, and liver iron burden of all PCT patients were higher than those of nonporphyric controls. The highest values were found in PCT patients homozygous for the Cys282Tyr mutation. Of the patients studied, 59% were HCV positive (compared with 1.8% of the population), and 46% consumed more than 70 g of alcohol daily. Of the female patients, 63% were ingesting estrogens. Hepatic damage was most marked in patients with the Cys282Tyr/Cys282Tyr genotype who had HCV and drank heavily. Homozygosity for the Cys282Tyrmutation and HCV are the greatest risk factors for expression of PCT, and in most patients, more than 1 risk factor was identified. It was common for patients with HCV to consume alcohol. Patients with PCT should be screened for HFE mutations and for HCV.Keywords
This publication has 59 references indexed in Scilit:
- Three new mutations in the uroporphyrinogen decarboxylase gene in familial porphyria cutanea tardaHuman Mutation, 1999
- Porphyria Cutanea TardaSeminars in Liver Disease, 1998
- Analysis of uroporphyrinogen decarboxylase complementary DNAs in sporadic porphyria cutanea tardaGastroenterology, 1993
- Uroporphyrinogen decarboxylase: a splice site mutation causes the deletion of exon 6 in multiple families with porphyria cutanea tarda.Journal of Clinical Investigation, 1990
- Heterogeneity of familial porphyria cutanea tarda.Journal of Medical Genetics, 1988
- IMMUNOREACTIVE UROPORPHYRINOGEN DECARBOXYLASE IN THE LIVER IN PORPHYRIA CUTANEA TARDAThe Lancet, 1985
- An inherited enzymatic defect in porphyria cutanea tarda: decreased uroporphyrinogen decarboxylase activity.Journal of Clinical Investigation, 1976
- STUDIES OF THE CLINICAL AND METABOLIC EFFECTS OF PHLEBOTOMY TREATMENT IN PORPHYRIA CUTANEA TARDAActa Medica Scandinavica, 1968
- Allgemeinsymptome der späten Hautporphyrie (Porphyria cutanea tarda) als Hinweise für deren BehandlungDeutsche Medizinische Wochenschrift (1946), 1961
- ADULT FORM OF CHRONIC PORPHYRIA WITH CUTANEOUS MANIFESTATIONSJAMA, 1951